Etoposide

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc ATC codes: L01CB01

Indication	Myeloid leukaemia ICD11 code: 2B33.1
INN	Etoposide
Medicine type	Chemical agent
List type	Complementary
Formulations	**Parenteral > General injections > IV:** 20 mg per mL in 5 mL ampoule ; 100 mg in vial powder for injection (as phosphate) **Oral > Solid:** 100 mg capsule ; 50 mg capsule
EML status history	First added in 2021 (TRS 1035) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer
Wikipedia	Etoposide
DrugBank	Etoposide

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of etoposide (Powder for injection: 100 mg (as phosphate) in vial) to the EML and EMLc.